Cefepime/tazobactam - Wockhardt

Drug Profile

Cefepime/tazobactam - Wockhardt

Alternative Names: FEP-TAZ; WCK 4282

Latest Information Update: 09 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Wockhardt
  • Class Antibacterials; Small molecules
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Gram-negative infections

Most Recent Events

  • 12 Apr 2017 Pharmacokinetics and adverse event data from a phase I trial in Gram-negative infections presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID - 2017)
  • 31 May 2016 Chemical information added
  • 09 Apr 2016 Pharmacokinetics and adverse events data from a clinical trial in Volunteers for Gram negative infections presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top